In the fields of biomedicine and healthcare, continuous technological innovation is the core driving force for enterprise development. Recently, good news came from the National Intellectual Property Administration: Wuxi Further Pharmaceutical Co., Ltd. (hereinafter referred to as "Further Pharmaceutical") has made significant progress in core technology R&D—our independently developed invention patent application has been officially accepted by the National Intellectual Property Administration!
01 Patent approved, innovation strength recognized by authorities
According to Article 28 of the Patent Law of the People's Republic of China and its implementing rules, the National Intellectual Property Administration has reviewed the patent applications submitted by Further Pharmaceutical and officially issued the Patent Application Acceptance Notice on October 15, 2026.
The invention patent accepted this time marks a substantial breakthrough for Further Pharmaceutical's research in related fields, with its technical strength and innovation capability recognized by authoritative national authorities.
02 Core Technology: Redefining the hydrogel preparation process
The invention patent information for this application is as follows:
* Patent Title: A succinic anhydride preacylated animal-derived type I collagen-PDRN covalent crosslinked hydrogel and its preparation method
* Application Number: 202611597684.7
* Applicant: Wuxi Further Pharmaceutical Co., Ltd
* Inventors: Wu Yueyue, Tang Shiqi, Wu Pengcheng
Technical Analysis:
This patented technology focuses on the preparation of "collagen-PDRN covalent crosslinked hydrogel." By introducing advanced processes such as "preacylation of succinic anhydride," it aims to address technical pain points in traditional preparation processes, further enhancing the biocompatibility, stability, and functionality of hydrogels, and laying a solid technical foundation for deeper applications in biomedical materials, functional skincare products, and regenerative medicine.
03 Deep Focus on R&D, Continuously Empowering Industry Development
Further Pharmaceutical has always regarded "technological innovation" as the company's primary strategy for development. The formal acceptance of this invention patent is not only an important step in the company's intellectual property layout but also a vivid reflection of our relentless pursuit of product quality and cutting-edge technology.
In the future, Wuxi Further Pharmaceutical will continue to increase investment in scientific research, uphold a rigorous and pragmatic scientific attitude, and continue to deepen its efforts in the research and application of collagen and related bioactive substances, striving to provide consumers and the industry with higher-quality, safer, and more technologically advanced products and solutions.
Conclusion:
Innovation is endless, and the future is full of promise. We will continue to forge ahead, using technology to protect health, and forging quality with professionalism!
Wuxi Further pharmceutical. co., Litnbsp; manufactures Palmitoylethanolamide (CAS 544-31-0) powder micronized (2-10um) or granular 20-60 mesh, Purity;99%.
Wu Xi Further Pharmaceutical Co.,Ltd
Main Products
Palmitoylethanolamide(PEA) Micro (CAS 544-31-0)
Spermidine trihydrochloride(CAS 334-50-9)
Pterostilbene(CAS 537-42-8)
Luteolin (CAS 491-70-3)
Voglibose (CAS 83480-29-9) JP GMP
Mailbox:wuxifurther@gmail.com
Whatsapp:+86 18036885286
